RxDoctor Payments Data

Steven Popper, MD

Pulmonary Disease · Escondido, CANPI 1679849012

Payments from drug & device makers

$4,244in general payments, 2019–2025

Across 60 payments — averaging $70.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • GSK$472
  • Philips North America LLC$110
  • Genentech USA, Inc.$86
  • Inspire Medical Systems, Inc.$49
  • Baxter Healthcare$38
  • plus $207 from 9 others

What the payments were for

  • Food & beverage$1,21029%
  • Education$3,03471%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,244 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$117,178
Medicare patients
371
Services billed
1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate54$738,019
Trelegy ElliptaFluticasone/Umeclidin/Vilanter236$182,963
Spiriva RespimatTiotropium Bromide120$79,046
Fasenra PenBenralizumab12$66,646
Stiolto RespimatTiotropium Br/Olodaterol Hcl99$65,198
XolairOmalizumab13$41,715
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr79$40,288
Breo ElliptaFluticasone/Vilanterol77$33,875
Combivent RespimatIpratropium/Albuterol Sulfate43$28,394
Arnuity ElliptaFluticasone Furoate72$23,630
EliquisApixaban36$21,239
SymbicortBudesonide/Formoterol Fumarate66$16,955
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$16,813
Atrovent HfaIpratropium Bromide30$16,247
Incruse ElliptaUmeclidinium Bromide43$16,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$20$910,657316 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$472$296,868507 claims
PfizerEliquis$11$21,23936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Escondido

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →